Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 2:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 405 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Primary Immune Deficiency Disease Clear all
Completed Phase 3 Interventional Results available

Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)

NCT00457015
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
ecallantide, Phosphate Buffer Saline (PBS), pH 7.0
Drug
Lead sponsor
Shire
Industry
Eligibility
10 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
42
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Berkeley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 2, 2026, 2:57 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

NCT02584959
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
C1 esterase inhibitor [human] liquid, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
12 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
Scottsdale, Arizona • Santa Monica, California • Walnut Creek, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 2, 2026, 2:57 AM EDT
Completed Phase 2 Interventional Results available

CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12

NCT01095510
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
CINRYZE
Biological
Lead sponsor
Shire
Industry
Eligibility
2 Years to 11 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
8
States / cities
Colorado Springs, Colorado • Tampa, Florida • Chevy Chase, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Oct 2, 2026, 2:57 AM EDT
Not listed Phase 1Phase 2 Interventional

Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency

NCT03315078
View directory record Official record
Conditions
X-Linked Combined Immunodeficiency Diseases
Interventions
CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1α-hγc-OPT, Palifermin, Busulfan
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 40 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Oct 2, 2026, 2:57 AM EDT
Terminated Not applicable Interventional Results available

Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation

NCT01319851
View directory record Official record
Conditions
Thalassemia, Sickle Cell Disease, Glanzmann Thrombasthenia, Wiskott-Aldrich Syndrome, Chronic-granulomatous Disease, Severe Congenital Neutropenia, Leukocyte Adhesion Deficiency, Schwachman-Diamond Syndrome, Diamond-Blackfan Anemia, Fanconi Anemia, Dyskeratosis-congenita, Chediak-Higashi Syndrome, Severe Aplastic Anemia
Interventions
Alefacept
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Oct 2, 2026, 2:57 AM EDT
Recruiting Phase 2 Interventional

EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection

NCT03266653
View directory record Official record
Conditions
Epstein-Barr Virus Infections, Primary Immune Deficiency Disorder
Interventions
cytotoxic t-lymphocytes
Drug
Lead sponsor
New York Medical College
Other
Eligibility
1 Month to 79 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 2, 2026, 2:57 AM EDT
Recruiting No phase listed Observational

Familial Investigations of Childhood Cancer Predisposition

NCT03050268
View directory record Official record
Conditions
Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML, BAP1 Tumor Predisposition Syndrome, Carney Complex, Choroid Plexus Carcinoma, Constitutional Mismatch Repair Deficiency Syndrome, Diamond-Blackfan Anemia, DICER1 Syndrome, Dyskeratosis Congenita, Emberger Syndrome, Familial Acute Myeloid Leukemia, Familial Adenomatous Polyposis, Fanconi Anemia, Familial Cancer, Familial Wilms Tumor, Familial Neuroblastoma, GIST, Hereditary Breast and Ovarian Cancer, Hereditary Paraganglioma-Pheochromocytoma Syndrome, Hodgkin Lymphoma, Juvenile Polyposis, Li-Fraumeni Syndrome, Lynch Syndrome, MDS, Melanoma Syndrome, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2, Neuroblastoma, Neurofibromatosis Type 1, Neurofibromatosis Type II, Nevoid Basal Cell Carcinoma Syndrome, Non Hodgkin Lymphoma, Noonan Syndrome and Other Rasopathy, Overgrowth Syndromes, Pancreatic Cancer, Peutz-Jeghers Syndrome, Pheochromocytoma/Paraganglioma, PTEN Hamartoma Tumor Syndrome, Retinoblastoma, Rhabdoid Tumor Predisposition Syndrome, Rhabdomyosarcoma, Rothmund-Thomson Syndrome, Tuberous Sclerosis, Von Hippel-Lindau Disease
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2037
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 2, 2026, 2:57 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)

NCT03597594
View directory record Official record
Conditions
Severe Combined Immunodeficiency
Interventions
Anti-thymocyte globulin (rabbit), Busulfan, Fludarabine, Thiotepa, CliniMACS, Donor Lymphocyte Infusion
Drug · Device · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Months and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 2, 2026, 2:57 AM EDT
Completed No phase listed Observational

Identifying Emergency Room Patients Who Have Recently Been Infected With HIV

NCT00001130
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2008 · Synced Oct 2, 2026, 2:57 AM EDT
Completed Phase 1 Interventional

Stem Cell Gene Therapy to Treat X-Linked Severe Combined Immunodeficiency (XSCID)

NCT00028236
View directory record Official record
Conditions
Severe Combined Immunodeficiency
Interventions
Gene-Transduced Autologous CD34+ Stem Cells
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Months to 20 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 2, 2026, 2:57 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

A Community-University Approach to Preventing HIV

NCT03938077
View directory record Official record
Conditions
HIV/AIDS and Infections, Drug Abuse, Adolescent Behavior, Drug Usage, Alcohol Use, Mental Health, Tobacco Use, HIV Testing
Interventions
Storytelling 4 Empowerment
Device
Lead sponsor
University of Michigan
Other
Eligibility
16 Years to 21 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Ann Arbor, Michigan • Flint, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Oct 2, 2026, 2:57 AM EDT
Completed No phase listed Observational

Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency: A Natural History Study

NCT00001255
View directory record Official record
Conditions
Severe Combined Immunodeficiency
Interventions
ADA PBSC, ADA Umbilical Cord Blood Cells, Transduced Lymphocytes
Drug
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1990 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 2, 2026, 2:57 AM EDT
Completed Phase 1 Interventional

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

NCT03329950
View directory record Official record
Conditions
Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Cholangiocarcinoma, Bladder Urothelial Carcinoma, Pancreatic Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Head and Neck Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Other Solid Tumors, Diffuse Large B-cell Lymphoma (DLBCL), Mantle Cell Lymphoma, Indolent B-cell Lymphomas, Non-Hodgkin Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Waldenstrom's Disease, Marginal Zone Lymphoma, Mucosa Associated Lymphoid Tissue, Small Lymphocytic Leukemia
Interventions
CDX-1140, CDX-301, pembrolizumab, Chemotherapy
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
11
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Oct 2, 2026, 2:57 AM EDT
Terminated No phase listed Observational

Viral and Host Factors in the Transmission and Pathogenesis of HIV

NCT00219947
View directory record Official record
Conditions
HIV Infections
Interventions
blood draw
Other
Lead sponsor
Rockefeller University
Other
Eligibility
16 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2019
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 2, 2026, 2:57 AM EDT
Completed Phase 1 Interventional

Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells

NCT00692926
View directory record Official record
Conditions
MDS, Anemia, Aplastic, Inborn Errors of Metabolism, Congenital Marrow Failure, Congenital Immunodeficiency Syndrome
Interventions
ALDHbr Umbilical Cord Blood Cells
Biological
Lead sponsor
Joanne Kurtzberg, MD
Other
Eligibility
Up to 55 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 29, 2017 · Synced Oct 2, 2026, 2:57 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency

NCT04561115
View directory record Official record
Conditions
Primary Immunodeficiency
Interventions
Gamunex-C, IVIG-PEG
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Birmingham, Alabama • North Palm Beach, Florida • South Bend, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 2, 2026, 2:57 AM EDT
Recruiting No phase listed Observational

Detection and Characterization of Infections and Infection Susceptibility

NCT00404560
View directory record Official record
Conditions
Immune Deficiencies
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Month to 100 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 2, 2026, 2:57 AM EDT
Completed Phase 2 Interventional Results available

Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients

NCT01359969
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
rhC1INH
Drug
Lead sponsor
Pharming Technologies B.V.
Industry
Eligibility
2 Years to 13 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 2, 2026, 2:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Project RETAIN: Providing Integrated Care for HIV-Infected Crack Cocaine Users

NCT01614106
View directory record Official record
Conditions
HIV, AIDS, Substance Abuse
Interventions
Retention Clinic
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2021
U.S. locations
2
States / cities
Miami, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Oct 2, 2026, 2:57 AM EDT
Completed Phase 3 Interventional Results available

Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%

NCT02269163
View directory record Official record
Conditions
Primary Immunodeficiency
Interventions
Immune Globulin Intravenous, Prometic's Immune Globulin Intravenous 10%
Biological
Lead sponsor
Prometic Biotherapeutics, Inc.
Industry
Eligibility
2 Years to 80 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
13
States / cities
Irvine, California • Los Angeles, California • Centennial, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 2, 2026, 2:57 AM EDT
Completed No phase listed Observational

Developing Newborn Screening for Infants With Primary Immunodeficiency

NCT00113464
View directory record Official record
Conditions
Immune System Diseases
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 2, 2026, 2:57 AM EDT
Withdrawn Not applicable Interventional

Pancreatic Cancer Screening of High-Risk Individuals in Arkansas

NCT02309632
View directory record Official record
Conditions
Pancreatic Neoplasms, Peutz-Jegher's Syndrome, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ataxia Telangiectasia, Familial Atypical Mole-Malignant Melanoma Syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Hereditary Pancreatitis
Interventions
Pancreatic Cancer Screening Pathway 1, Pancreatic Cancer Screening Pathway 2
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Oct 2, 2026, 2:57 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Evaluate Bacteriophage as a Useful Immunogen in Patients With Primary Immune Deficiency Diseases (PIDD)

NCT01617122
View directory record Official record
Conditions
Primary Immune Deficiency Diseases
Interventions
Bacteriophage OX174
Biological
Lead sponsor
University of South Florida
Other
Eligibility
2 Years to 85 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2015
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jul 17, 2012 · Synced Oct 2, 2026, 2:57 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor

NCT02247739
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Recombinant human C1 inhibitor, Placebo
Biological · Other
Lead sponsor
Pharming Technologies B.V.
Industry
Eligibility
13 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Tampa, Florida • St Louis, Missouri • Lake Oswego, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 2, 2026, 2:57 AM EDT